Dynamics of reverse cholesterol transport: Protection against atherosclerosis

Atherosclerosis

Volumn 161, Issue 2, 2002, Pages 245-254

  Sviridov, Dmitri ^a   Nestel, Paul ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Atherosclerosis; High density lipoprotein; Pre 1 HDL; Reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CELL MEMBRANE TRANSPORT; CHOLESTEROL ESTERIFICATION; CHOLESTEROL TRANSPORT; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVERSE CHOLESTEROL TRANSPORT; REVIEW; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; ARTERIOSCLEROSIS; BIOLOGICAL TRANSPORT; CHOLESTEROL, HDL; HUMANS; PRIMARY PREVENTION; SENSITIVITY AND SPECIFICITY;

EID: 0036121299     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00677-3     Document Type: Review

References (117)

1. High density lipoprotein cholesterol and mortality. The Framingham Heart Study
2. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport
3. High-density lipoprotein-the clinical implications of recent studies
4. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
5. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
6. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
7. The plasma lecithins:cholesterol acyltransferase reaction
8. Molecular physiology of the reverse cholesterol transport
9. Interaction of free apolipoproteins with macrophages. Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol
10. Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides
11. Identification of a sequence of apolipoprotein A-I associated with activation of lecithin:cholesterol acyltransferase
12. High density lipoprotein receptors, binding proteins, and ligands
13. Plasma lipid transfer proteins
14. Lipoproteins of human peripheral lymph
15. Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma
16. Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration
17. High levels of human apolipoprotein A-I and high density lipoproteins in transgenic mice do not enhance efflux of cholesterol from a depot of injected lipoproteins. Relevance to regression of atherosclerosis?
18. ApoA-I knockout mice: Characterization of HDL metabolism in homozygotes and identification of a post-RNA mechanism of apoA-I up-regulation in heterozygotes
19. Lack of ApoA-I is not associated with increased susceptibility to atherosclerosis in mice
20. HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis
21. Characterization of atherosclerosis in a patient with familial high-density lipoprotein deficiency
22. Familial HDL deficiency due to marked hypercatabolism of normal apoA-I
23. Severe familial HDL deficiency in French-Canadian kindreds. Clinical, biochemical, and molecular characterization
24. Genetic defects in lipoprotein metabolism
25. A novel mutant, ApoA-I nichinan (Glu235→0), is associated with low HDL cholesterol levels and decreased cholesterol efflux from cells
26. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes
27. Reverse cholesterol transport
28. Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?
29. High density lipoproteins and arteriosclerosis: Role of cholesterol efflux and reverse cholesterol transport
30. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study
31. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene
32. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia
33. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men
34. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules
35. Antioxidative activity of high density lipoproteins in vivo
36. High density lipoprotein and lipoprotein oxidation
37. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein
38. Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by a-tocopherol
39. HDL(3)-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate
40. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae
41. Phosphoproteins regulated by the interaction of high-density lipoprotein with human skin fibroblasts
42. Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol
43. Cyclic AMP stimulates efflux of intracellular sterol from cholesterol-loaded cells
44. Induction of cellular cholesterol efflux to lipid-free apolipoprotein A-I by cAMP
45. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway
46. High density lipoprotein metabolism
47. Associations of the HDL2 and HDL3 cholesterol subfractions with the development of ischemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies
48. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study
49. Differential role of apolipoprotein AI-containing particles in cholesterol efflux from adipose cells
50. Modulation of cholesterol efflux from Fu5AH hepatoma cells by the apolipoprotein content of high density lipoprotein particles. Particles containing various proportions of apolipoproteins A-I and A-II
51. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre- beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport
52. Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma
53. Selective uptake of cholesteryl esters from high-density lipoprotein-derived LpA-I and LpA-I:A-II particles by hepatic cells in culture
54. Cholesterol efflux from human monocyte-derived macrophages in the presence of LpA-I:A-II
55. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease
56. Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease
57. Turnover of plasma esterified cholesterol in normocholesterolemic and hypercholesterolemic subjects and its relation to body build
58. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein
59. Quantitation of pre beta-HDL-dependent and nonspecific components of the total efflux of cellular cholesterol and phospholipid
60. Cell-derived unesterified cholesterol cycles between different HDLs and LDL for its effective esterification in plasma
61. Two-dimensional electrophoresis of plasma lipoproteins: Recognition of new apo A-I-containing subpopulations
62. Presence and formation of 'free apolipoprotein A-I-like' particles in human plasma
63. Role of free apolipoprotein A-I in cholesterol efflux. Formation of pre-alpha- migrating high-density lipoprotein particles
64. Cholesterol transport between cells and high density lipoprotein subfractions from obese and lean subjects
65. Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins
66. Cycling of apolipoprotein A-I between lipid-associated and lipid-free pools
67. Apolipoprotein-mediated cellular cholesterol/phospholipid efflux and plasma high density lipoprotein level in mice
68. Cellular cholesterol efflux in heterozygotes for tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size
69. The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines
70. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes
71. Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes
72. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes
73. Lecithin:cholesterol acyltransferase overexpression generates hyperalpha-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits
74. Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner
75. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis
76. Expression of human lecithin:cholesterol acyltransferase in transgenic mice: Effects on cholesterol efflux, esterification, and transport
77. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase
78. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice
79. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein
80. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase
81. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: The Framingham study
82. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study
83. Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice
84. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice
85. Hepatic lipase deficiency
86. Hyperalphalipoproteinemia: Characterization of a cardioprotective profile associating increased high-density lipoprotein2 levels and decreased hepatic lipase activity
87. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor
88. Cubilin, the endocytic receptor for intrinsic factor-vitamin B(12) complex, mediates high-density lipoprotein holoparticle endocytosis
89. Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins
90. The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein
91. Megalin and cubilin: Synergistic endocytic receptors in renal proximal tubule
92. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism
93. Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol
94. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse
95. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels
96. Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics
97. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux
98. Defective forebrain development in mice lacking gp330/megalin
99. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans
100. Cell cholesterol efflux: Integration of old and new observations provides new insights
101. Depletion of pre beta 1LpA1 and LpA4 particles by mast cell chymase reduces cholesterol efflux from macrophage foam cells induced by plasma
102. Prebeta1-high-density lipoprotein increases in coronary artery disease
103. Prebeta-migrating high density lipoprotein: Quantitation in normal and hyperlipidemic plasma by solid phase radioimmunoassay following electrophoretic transfer
104. High prebeta1-HDL levels in hypercholesterolemia are maintained by probucol but reduced by a low-cholesterol diet
105. A new sandwich enzyme immunoassay for measurement of plasma pre-beta1-HDL levels
106. Prebeta1-high-density lipoprotein (prebeta1-HDL) concentration can change with low-density lipoprotein-cholesterol (LDL-C) concentration independent of cholesteryl ester transfer protein (CETP)
107. Altered properties of high density lipoprotein subfractions in obese subjects
108. Effect of weight reduction on the distribution of apolipoprotein A-I in HDL subfractions in obese non-insulin-dependent diabetic subjects
109. Effects of insulin therapy and glycemic control on distribution of HDL alpha and pre-beta subfractions in non insulin-dependent diabetic subjects
110. Bezafibrate increases Prebeta1-HDL at the expense of HDL(2b) in hypertriglyceridemia
111. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages
112. Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I
113. Deletion of the pro-peptide of apolipoprotein A-I reduces protein expression, but stimulates effective conversion of preβ-HDL to α-HDL
114. Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity
115. Effect of adiposity on plasma lipid transfer protein activities: A possible link between insulin resistance and high density lipoprotein metabolism
116. Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin
117. Cholesterol metabolism in human obesity